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ABSTRACT
Background. Chemotherapy-associated liver injury is a
major cause for concern when treating patients with colo-
rectal liver metastases. The aim of this review was to
determine the pathological effect of specific chemotherapy
regimens on the hepatic parenchyma as well as on surgical
morbidity, mortality and overall survival.
Methods. A systematic review of the published literature
and a meta-analysis were performed. For each of the
variables under consideration, the effects of different che-
motherapy regimens were determined by calculation of
relative risks by a random-effects model.
Results. Hepatic parenchymal injury is regimen specific,
with oxaliplatin-based regimens being associated with
grade 2 or greater sinusoidal injury (number needed to
harm 8; 95 % confidence interval [CI] 6.4–13.6), whereas
irinotecan-based regimens associated with steatohepatitis
(number needed to harm 12; 95 % CI 7.8–26). The use of
bevacizumab alongside FOLFOX reduces the risk of grade
2 or greater sinusoidal injury (relative risk 0.34; 95 % CI
0.15–0.75).
Conclusions. Chemotherapy before resection of colorectal
liver metastases is associated with an increased risk of
regimen-specific liver injury. This liver injury may have
implications for the functional reserve of the liver for
patients undergoing major hepatectomy for colorectal liver
metastases.
In 2008, the incidence of colorectal cancer within Eur-
ope was estimated to be 436,000, with 212,000 deaths
directly attributed to this disease.1 Fifty percent of patients
with a primary colorectal tumor will go on to develop
metastatic disease in the liver, and in 25 % of patients, this
is present at the time of diagnosis.2–4 In patients with liver-
only metastases, the gold standard of treatment is liver
resection, the aim of which is to remove all metastatic
disease. When this is achieved, overall 5-year survival rates
in the order of 50–60 % have been reported, compared to
19.5 % for patients in whom this is not possible.5,6 How-
ever, for those patients with inoperable disease, the
mainstay of treatment remains systemic chemotherapy in
conjunction with recent additions such as radioemboliza-
tion and the more established ablative (e.g., microwave and
radiofrequency ablation) therapies.7–9 The advent of mod-
ern chemotherapeutics such as oxaliplatin and irinotecan,
as well as biological treatments such as bevacizumab (anti-
vascular endothelial growth factor A [VEGF-A]) and ce-
tuximab (anti-epidermal growth factor receptor [EGFR]),
have seen median survival rates in patients with inoperable
metastatic colorectal cancer entered into phase III trials rise
from 6 to 12 months in the mid-1990s to 18–24 months in
the latter part of the last decade.6
It is increasingly recognized that in those patients with
initially inoperable liver metastases, chemotherapy can be
effectively provided to downstage disease such that a
potentially curative resection can be offered.10–12 This
strategy, referred to as conversion chemotherapy, is a
major reason for the yearly increase in the number of liver
resections being performed for colorectal liver metastases.6
The 5-year survival in patients whose disease is success-
fully downstaged and who undergo subsequent surgical
resection is in the order of 30 %.13 In addition, there is
 The Author(s) 2012. This article is published with open access
at Springerlink.com
First Received: 30 January 2012;
Published Online: 6 July 2012
S. M. Robinson, MRCS
e-mail: s.m.robinson@ncl.ac.uk
Ann Surg Oncol (2012) 19:4287–4299
DOI 10.1245/s10434-012-2438-8
some evidence emerging that the routine use of perioper-
ative chemotherapy, even in patients with initially operable
disease, may improve long-term survival after surgery.14
Together, this means that an ever-increasing number of
patients undergoing liver resection to treat colorectal liver
metastases will have received some form of preoperative
chemotherapy.
Modern chemotherapy regimens used in the manage-
ment of metastatic colorectal cancer use traditional
5-fluorouracil (5-FU) and folinic acid in combination with
either oxaliplatin or irinotecan. Often 5-FU, which is pro-
vided parenterally, is substituted by its oral prodrug,
capecitabine.15 In recent years, monoclonal antibodies
directed against VEGF-A (bevacizumab) and EGFR (ce-
tuximab, panitumumab) have also been provided in an
attempt to improve tumor response rates.5
Many observational studies have been published
claiming that the use of chemotherapy before surgery can
lead to injury to the hepatic parenchyma. This injury has
been reported to take the form of hepatic steatosis, ste-
atohepatitis, nodular regenerative hyperplasia, and
sinusoidal obstruction syndrome, and there are numerous
reviews on this subject.16–18 Nonetheless, a meta-analysis
has never been performed.
The most effective chemotherapy strategy in patients
with inoperable colorectal liver metastases is one that
provides maximal disease downstaging while having a
minimal effect on the non-tumor-bearing liver, subse-
quently reducing surgical morbidity and mortality.
Similarly, in the neoadjuvant setting, the aim should be to
minimize the risk of postoperative recurrence without
increasing the risk associated with that operation. At the
present time, however, the true magnitude of the effect of
chemotherapy on the hepatic parenchyma and its sub-
sequent effect on surgical morbidity and mortality remains
ill defined because of the heterogeneous nature of pub-
lished case series.
The aim of this review was to determine what the effect
of specific chemotherapy regimens is on the hepatic
parenchyma.
METHODS
Literature Search
A systematic search for reports published between Jan-
uary 1, 1996, and June 31, 2011, was performed on
Medline, Embase, and the Cochrane Library. Searches
included the keywords ‘‘liver resection,’’ ‘‘hepatectomy,’’
‘‘chemotherapy,’’ ‘‘steatosis,’’ ‘‘steatohepatitis,’’ and
‘‘sinusoidal obstruction syndrome.’’ In addition, the MeSH
headings ‘‘surgical procedures, operative,’’ ‘‘colorectal
neoplasms,’’ ‘‘hepatectomy,’’ ‘‘drug-induced liver injury,’’
and ‘‘fatty liver’’ were used. In addition to these database
searches, the reference lists of review articles were hand-
searched to identify further reports.
Screening of Identified Reports
Initially the titles of potentially eligible studies were
screened and case reports, commentaries/editorials,
reviews, animal studies, in vitro studies, and non-English
studies were rejected. At the next stage, abstracts of the
remaining studies were retrieved and reviewed for
potential relevance. The full text of articles whose
abstracts were identified as being of potential relevance
were then retrieved and assessed against the following
inclusion criteria, using a standard pro forma: those
included were patients undergoing treatment of colorectal
liver metastases only; either histological or outcome data
were provided for patients undergoing resection of colo-
rectal liver metastases; and there were a minimum of 10
patients per group. Studies in the format of a published
abstract were excluded. Figure 1 summarizes the process
of study selection.
Data Extraction
Data including study design characteristics, histological
scoring of the liver parenchyma, perioperative morbidity,
and mortality were extracted for each study. Close atten-
tion was paid to the kin relationship of studies—that is,
multiple publications that use the same patient cohorts.
Where there was potential duplication of data, only the
study that provided the largest patient number to assess a
given outcome was used. Study quality was assessed
according to the Newcastle–Ottawa score for nonrandom-
ized studies.19 The level of evidence for each study was
scored according to the Oxford Centre for Evidence Based
Medicine scale.20 All data extraction from original articles
was performed on two separate occasions and cross-refer-
enced to ensure accuracy.
The presence of liver injury was defined according to
histological criteria as follows: hepatic steatosis (the pres-
ence of either macro- or microvesicular steatosis of all
grades); steatosis [30 % (hepatic steatosis involving more
than 30 % of hepatocytes); steatohepatitis (the presence of
the combination of steatohepatitis, inflammatory infiltrates,
and ballooning degeneration of hepatocytes as assessed by
a recognized scoring system such as that by Kleiner
et al.21); and sinusoidal dilatation (dilatation of the hepatic
sinusoids graded according the method of Rubbia-Brandt
et al.22).
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Statistical Analysis
A meta-analysis was performed by using histological
scoring as the outcome measures in accordance with the
Meta-analysis of Observational Studies in Epidemiology
Guidelines.23 Analysis was performed by Review Manager
(RevMan) software, version 5.1 (Nordic Cochrane Centre,
Copenhagen, Denmark). The effects of preoperative che-
motherapy regimens on histological scores of liver injury
and perioperative outcome were estimated by using a
pooled relative risk (RR) along with 95 % confidence
interval using a random-effects model.24 Studies were
weighted according to population size. Overall effect size
was determined with the Z test and statistical significance
set at a level of p = 0.05. Heterogeneity across studies
was assessed with the I2 statistic and through forest
plot inspection. Data from observational studies and
randomized, controlled studies were not included within
the same analysis.
RESULTS
Description of Studies
Of the 14,619 reports identified within the initial search,
28 were considered appropriate for inclusion within this
systematic review. Of these studies, most were considered
to be of evidence level 2b or greater (n = 26; 93 %). All
but one of the included studies were observational in
character. The potential for overlap of participants was
noted in 15 (54 %) of the 28 included studies. The char-
acteristics of these studies, along with their key findings,
are summarized in Table 1.
Hepatic Steatosis/Steatohepatitis
Nonalcoholic fatty liver disease exists as a spectrum of
pathological changes in the hepatic parenchyma, pro-
gressing from simple steatosis to steatohepatitis and
eventually hepatic fibrosis and cirrhosis. The severity of
hepatic steatosis is determined by the proportion of
involved hepatocytes as judged by histological review of
hematoxylin and eosin-stained sections of the liver. A
variety of grading systems exist, although the most com-
monly used is that proposed by Kleiner et al.,21 which
classifies steatosis as absent (\5 % hepatocytes), mild
(5–33 % hepatocytes), moderate ([33–66 % hepatocytes),
and severe ([66 % of hepatocytes). This grading system is
not uniform with others, using a cutoff of 30 and 60 % to
define moderate and severe steatosis, respectively.25,26
Given the inherent interobserver variability in assessing
steatosis, the minor differences in these grading systems
are unlikely to be significant, and as such, a cutoff of 30 or
33 % was considered to be equivalent for the purposes of
this analysis.27,28
The importance of hepatic steatosis in patients under-
going liver resection was demonstrated in a meta-analysis
by de Meijer et al., which showed its presence to be a risk
factor for increased perioperative morbidity and mortality
in patients undergoing major hepatic resection ([three
Couinaud segments). In patients with steatosis [30 %, the
risk of death after major resection increased nearly three-
fold, and as such, this was the cutoff we used to identify
patients with high-risk steatosis.29
Thirteen studies reported the incidence of hepatic stea-
tosis in 1,508 patients undergoing liver resection for
colorectal liver metastases, 799 of whom had received
preoperative chemotherapy. Overall, there was no associ-
ation between the use of preoperative chemotherapy and
FIG. 1 Summary of study selection process
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TABLE 1 Summary of included studies
Study Years Study
type
Comparisons n NOS Evidence
level
Key findings Overlap with
other studies
Adam
et al.67
2010 CS(R) Neoadjuvant chemotherapy
versus surgery alone
1471 7 2b The use of preoperative
chemotherapy does not seem to
offer any benefit to patients with a
solitary metachronous colorectal
liver metastases
Data from
LiverMet
survey (i.e.,
multiple
centers)
Aloia et al.68 2006 CS(R) Neoadjuvant (Ox based)
chemotherapy versus
surgery alone
75 8 2b The main hepatic injury after Ox-
based chemotherapy is vascular
not steatosis. The risk of
complications is related to the
duration of chemotherapy
Aloysius
et al.69
2007 CC(R) Neoadjuvant (FOLFOX-4)
chemotherapy versus
surgery alone
50 7 3b The use of neoadjuvant FOLFOX-4
is associated with hepatic steatosis
and sinusoidal dilatation
Nordlinger
et al.14
2008 RCT Perioperative (FOLFOX)
chemotherapy versus
surgery alone
364 1b Preoperative FOLFOX-4
chemotherapy increases the risk of
perioperative complications but
improves progression free survival
Multicenter
RCT
Gomez et al.52 2007 CS(R) Hepatic steatosis versus no
hepatic steatosis
386 8 2b Hepatic steatosis increases the
morbidity of liver resection
70
Gomez-
Ramirez
et al.30
2010 CS(P) Neoadjuvant chemotherapy
versus surgery alone
45 6 2b Neoadjuvant irinotecan is associated
with an increased risk of
steatohepatitis
Hewes et al.71 2007 CS(R) Neoadjuvant chemotherapy
versus surgery alone
67 8 2b Neoadjuvant Ox-based
chemotherapy increases the risk
associated with liver resection
Hubert et al.72 2010 CS(R) Neoadjuvant chemotherapy
versus surgery alone
114 8 2b Neoadjuvant chemotherapy is
associated with sinusoidal
congestion but has no impact on
perioperative outcome
Kandutsch
et al.73
2008 CS(R) Neoadjuvant (Ox based)
chemotherapy versus
surgery alone
63 8 2b Sinusoidal obstruction but not
steatohepatitis occurs as a
consequence of Ox-based
chemotherapy
40,45
Karoui et al.74 2006 CS(R) Neoadjuvant chemotherapy
versus surgery alone
67 7 2b Prolonged chemotherapy injures the
hepatic parenchyma and increases
the morbidity of liver resection
when performed under total
vascular exclusion
Kishi et al.75 2010 CS(R) Neoadjuvant FOLFOX
versus neoadjuvant
FOLFOX and
bevacizumab
219 8 2b Extended preoperative chemotherapy
increases the risk of parenchymal
injury without improving
pathological response
33,44,46,76
Klinger
et al.45
2009 CS(R) Neoadjuvant (Ox based)
chemotherapy versus
neoadjuvant (Ox based)
chemotherapy and
bevacizumab
99 7 2b Bevacizumab protects against
sinusoidal obstruction syndrome
but does not improve tumor
response to Ox-based
chemotherapy
40,73
Komori
et al.42
2010 CS(R) Neoadjuvant (FOLFOX)
chemotherapy versus
surgery alone
27 8 2b FOLFOX use results in parenchymal
injury but has no effect on
perioperative morbidity and
mortality
Makowiec
et al.41
2011 CS(R) Neoadjuvant chemotherapy
versus surgery alone
102 7 2b Neither preoperative chemotherapy
or the presence of parenchymal
injury affect perioperative
outcome
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TABLE 1 continued
Study Years Study
type
Comparisons n NOS Evidence
level
Key findings Overlap with
other studies
Mehta et al.26 2008 CS(R) Neoadjuvant chemotherapy
versus surgery alone
173 6 2b Ox-based chemotherapy is associated
with a vascular injury to the liver
parenchyma but this has no effect
on perioperative outcome
Nakano
et al.39
2008 CS(R) Neoadjuvant (Ox based)
chemotherapy versus
neoadjuvant (other
regimens) chemotherapy
90 8 2b Ox-based chemotherapy is associated
with an increased incidence of
sinusoidal injury. Sinusoidal injury
is associated with a poorer
outcome after major hepatectomy
25
O’Rourke
et al.77
2009 CS(P) Neoadjuvant chemotherapy
versus surgery alone
37 8 2b Liver specific MRI can accurately
predict the severity of
parenchymal injury
78
Ouaissi et al.79 2006 CS(R) Neoadjuvant chemotherapy
versus surgery alone
40 6 2b Preoperative chemotherapy does not
influence the outcome of liver
resection
Pawlik et al.31 2007 CS(R) Neoadjuvant chemotherapy
versus surgery alone
212 8 2b Neoadjuvant chemotherapy is
associated with parenchymal
injury in 20–30 % of patients. The
nature of the injury is regimen
specific
Ribero et al.46 2007 CS(R) Neoadjuvant (Ox based)
chemotherapy versus
neoadjuvant (Ox based)
chemotherapy and
bevacizumab
105 8 2b The addition of bevacizumab to Ox-
based chemotherapy reduces the
incidence of sinusoidal injury and
increases tumor response to
chemotherapy as assessed
histologically
33,44,75,76
Rubbia-
Brandt
et al.22
2004 CS(R) Neoadjuvant chemotherapy
versus surgery alone
153 6 2b Neoadjuvant Ox-based
chemotherapy is associated with
sinusoidal obstruction syndrome
44
Rubbia-
Brandt
et al.44
2010 CS(R) Neoadjuvant (Ox based)
chemotherapy versus
neoadjuvant (Ox based)
chemotherapy and
bevacizumab versus
surgery alone
385 6 2b Ox-based chemotherapy is associated
with sinusoidal obstruction
syndrome, the incidence of which
is reduced if provided alongside
bevacizumab
22,33,46,75,76
Ryan et al.32 2010 CS(R) Neoadjuvant chemotherapy
versus surgery alone
334 8 2b Neoadjuvant chemotherapy is
associated with a vascular injury to
the hepatic parenchyma but not
steatohepatitis
80
Sahajpal
et al.80
2007 CS(R) Neoadjuvant chemotherapy
versus surgery alone
96 7 2b Neoadjuvant chemotherapy does not
affect short term outcomes after
liver resection
32
Scoggins
et al.81
2008 CS(R) Neoadjuvant chemotherapy
versus surgery alone
186 8 2b Neoadjuvant chemotherapy does not
affect the morbidity associated
with liver resection
Tamandl
et al.40
2011 CS(R) Neoadjuvant chemotherapy
versus surgery alone
196 8 2b Ox-induced sinusoidal obstruction is
associated with poorer overall and
disease specific survival
45,73
Vauthey
et al.33
2006 CS(R) Neoadjuvant chemotherapy
versus surgery alone
406 8 2b Neoadjuvant irinotecan-based
chemotherapy is associated with
the development of steatohepatitis
44,46,75,76
Yebidela
et al.82
2005 CC(R) Neoadjuvant chemotherapy
versus surgery alone
64 8 3b Neoadjuvant chemotherapy does not
increase surgical morbidity or
mortality
Ox oxaliplatin, NOS Newcastle Ottawa Score, CS cohort study, CC case controlled study, RCT randomised controlled trial, (R) retrospective,
(P) prospective
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the presence of hepatic steatosis (RR 1.25; 95 % confi-
dence interval [CI] 0.99–1.57; p = 0.06). Similarly, no
association could be demonstrated between the incidence
of steatosis [30 % and the use of preoperative chemo-
therapy in 14 studies presenting data from 2,040 patients
(RR 1.25; 95 % CI 0.92–1.68; p = 0.15; Fig. 2a).
It is increasingly recognized that the nature of chemo-
therapy-associated liver injury is regimen specific. In the
case of oxaliplatin-based regimens, there was no associa-
tion with the development of hepatic steatosis overall (RR
1.30; 95 % CI 0.85–2.00; p = 0.23) or steatosis [30 %
(RR 0.98; 95 % CI 0.59–1.63; p = 0.95; Fig. 2b). Simi-
larly, when the effects of irinotecan-based regimens were
examined, it was not possible to demonstrate an increased
incidence of steatosis [30 % (RR 2.51; 95 % CI
0.79–7.90; p = 0.12; Fig. 2c). This latter analysis included
FIG. 2 Risk of developing hepatic steatosis [30 % in patients treated with preoperative chemotherapy (a) and specifically in those receiving
oxaliplatin-based regimens (b) or irinotecan-based regimens (c)
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four studies, among which there was marked heterogeneity
(I2 = 74 %; p = 0.01), with the two smaller studies
showing a markedly increased risk of steatosis [30 % in
those receiving irinotecan-based chemotherapy, whereas
the two larger studies demonstrated no such increase.30–33
One explanation for this heterogeneity in the included
studies may be related to the manner in which hepatic
steatosis is assessed: by review of hematoxylin and eosin-
stained sections by an expert pathologist. In 2009 El-Badry
et al. compared the grading of steatosis in 46 consecutive
patients undergoing liver resection by four expert liver
pathologists from three different countries. This study
found that there was marked discrepancy among patholo-
gists in the grading of steatosis, which grew more marked
as the degree of steatosis worsened.28 A further study by
Gawrieh et al.,27 has reported similar findings confirming
the potential importance of this phenomenon.
Steatohepatitis is distinguished from simple steatosis by
the presence of inflammatory infiltrates within the liver and
ballooning degeneration of hepatocytes.21 Nonalcoholic
steatohepatitis is most commonly associated with the
presence of type 2 diabetes mellitus, obesity, and metabolic
syndrome, meaning that the population prevalence of these
conditions will directly affect the frequency of steatohep-
atitis in patients presenting for liver resection.34 Studies in
patients undergoing bariatric surgery have suggested that in
patients with a body mass index (BMI) of [35 kg/m2, the
prevalence of steatohepatitis approaches almost 40 %.35
The presence of steatohepatitis is more worrying than
simple steatosis when undertaking major liver resection,
and its presence has been demonstrated to be associated
with increased surgical morbidity and mortality after
resection of colorectal liver metastases.33 It should be
highlighted that in this study, all deaths in patients with
steatohepatitis occurred in those who underwent combined
resection and radiofrequency ablation. The significance of
this is to emphasize that careful consideration needs to be
given to safety when performing extensive procedures in
patients with steatohepatitis.
Overall, the use of preoperative chemotherapy was
associated with a trend toward an increased incidence of
steatohepatitis and was of borderline statistical significance
(RR 1.89; 95 % CI 0.99–3.63; p = 0.05). If the analysis
was limited to those receiving irinotecan-based regimens,
however, there was a 3.45-fold increased risk of steato-
hepatitis when compared to those who were chemotherapy
naive (95 % CI 1.12–10.62; p = 0.03; Fig. 3), giving a
number needed to harm of 12 (95 % CI 7.8–26.5)—that is,
1 in every 12 patients treated with an irinotecan-based
chemotherapy regimen would be expected to develop ste-
atohepatitis as a result.
It can be seen that there is a moderate degree of heter-
ogeneity in the included studies that arises from that of
Ryan et al., who did not demonstrate any association
between irinotecan-based chemotherapy and the develop-
ment of steatohepatitis. This may in part be explained by
the observation that the mean time interval between the
cessation of chemotherapy and surgery in this study was
12 weeks as compared to 6 weeks in that of Vauthey et al.,
which demonstrated the strongest association between iri-
notecan use and steatohepatitis.32, 33
The duration of chemotherapy administration is also a
potential source of heterogeneity; however, this is only
reported in two studies. In the study of Ryan et al.,32
patients typically received a mean of 7.5 cycles of che-
motherapy, whereas in the study of Vauthey et al.,33
chemotherapy was administered for a median of 16 weeks.
The different manners of reporting these make it difficult to
make direct comparisons, although one cycle of chemo-
therapy typically lasts for 2 weeks, suggesting that both
studies are broadly similar in this regard.
As already discussed, patient characteristics, particularly
in regard to BMI and the prevalence of diabetes, may be
significant sources of heterogeneity when comparing the
prevalence of steatohepatitis between studies.36 In the
studies of Gomez-Ramirez et al. 30 and Pawlik et al.,31 both
of which reported a positive association between steato-
hepatitis and irinotecan, patients receiving irinotecan were
FIG. 3 Irinotecan-based chemotherapy is associated with an increased risk of steatohepatitis
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more likely to have a higher mean BMI (29.3 vs. 26.2 and
28.1 vs. 26.6 kg/m2, respectively). In the study of Vauthey
et al.,33 the incidence of steatohepatitis in patients with a
BMI of [25 kg/m2 was nearly twice that in those with
BMI of \25 kg/m2 (24.6 vs. 12.1 %). Multivariate analysis
in the study of Ryan et al. 32 demonstrated that the only
variable independently associated with steatohepatitis was
a BMI of [30 kg/m2. None of the included studies per-
formed prechemotherapy liver biopsies, and as such, it is
impossible to truly determine what effect background ste-
atosis has on the development of steatohepatitis after
irinotecan treatment.
Oxaliplatin-based regimens were not associated with an
increased risk of steatohepatitis (RR 1.17; 95 % CI
0.45–3.04; p = 0.75).
Sinusoidal Injury
Until the advent of modern chemotherapeutics, sinu-
soidal obstruction syndrome was considered a rare
phenomenon related to the ingestion of pyrrolizidine
alkaloids.37 More recently, sinusoidal obstruction syn-
drome has been described in patients receiving
myeloablative chemotherapy before bone marrow trans-
plantation and latterly in the treatment of colorectal liver
metastases.38 A key feature of sinusoidal obstruction syn-
drome is sinusoidal dilatation with associated hepatocyte
atrophy. Later changes include the development of perisi-
nusoidal fibrosis and nodular regenerative hyperplasia.
Most commonly, sinusoidal dilatation is graded according
to the method of Rubbia-Brandt et al. 22 (0 = absent,
1 = mild, 2 = moderate, 3 = severe), and a higher score
is thought to reflect a more severe injury to the hepatic
sinusoid.
Eight studies reported the incidence of sinusoidal dila-
tation (grades 1–3) in a total of 871 patients, 633 of whom
had received preoperative chemotherapy. The use of pre-
operative chemotherapy was associated with a 1.95-fold
increased risk of sinusoidal dilatation (95 % CI 1.46–2.61;
p \ 0.00001). Grade 2 sinusoidal injury or greater is gen-
erally accepted as being a more accurate mark of sinusoidal
injury and was reported in a total of 12 studies including a
total of 1,852 patients.22,38 The use of preoperative chemo-
therapy was associated with a 2.78-fold increase in risk of
grade 2 sinusoidal injury when compared to chemotherapy-
naive controls (95 % CI 1.35–5.69; p = 0.005; Fig. 4a).
However, there was a significant amount of heterogeneity in
the included studies (I2 = 66 %; p = 0.0007), again sug-
gesting that the chemotherapy regimen may be important in
determining who develops this pathology.
Six studies reported the incidence of sinusoidal
dilatation in 333 patients receiving oxaliplatin-based che-
motherapy as compared to 198 who were chemotherapy
naive. Oxaliplatin-based regimens were found to be asso-
ciated with a 2.22-fold increase in the risk of developing
sinusoidal dilatation in the non-tumor-bearing liver (95 %
CI 1.47–3.36; p = 0.0002). Similarly, a meta-analysis of
nine studies reporting grade 2 or greater sinusoidal injury
demonstrated that those receiving oxaliplatin-based regi-
mens were at a 4.36-fold increased risk of this when
compared to chemotherapy-naive control subjects (95 %
CI 1.36–13.97; p = 0.01; Fig. 4b), with the number needed
to harm being 8 (95 % CI 6.4–13.6). Surprisingly, there is a
large degree of heterogeneity in this latter analysis
(I2 = 69 %; p = 0.001), which arises predominantly from
the trial of Makowiec et al.,41 which reported an unusually
high incidence of grade 2 sinusoidal injury in patients who
were chemotherapy naive (17 of 34), which is much greater
than that reported in the other studies.
In a multivariate analysis of factors associated with
sinusoidal dilatation of all grades, Nakano et al.39 identified
receiving [six cycles of oxaliplatin-based chemotherapy to
be an independent risk factor (RR 3.2; p = 0.048). In
contrast, Tamandl et al.40 did not demonstrate any associ-
ation between the number of cycles of chemotherapy and
the development of grade 2 or greater sinusoidal dilatation
on univariate analysis (hazard ratio 0.70; p = 0.502). The
number of cycles of chemotherapy administered was
reported in seven out of nine studies included in the meta-
analysis in Fig. 4b and is summarized in Table 2. Differ-
ences in this regard did not explain the absence of
association between oxaliplatin-based chemotherapy and
grade 2 sinusoidal dilatation reported in the studies of
Makowiec et al.41 and Ryan et al.32
The time interval between cessation of chemotherapy
and liver resection were reported in five of nine studies
from the meta-analysis in Fig. 4b and are summarized in
Table 2. It can be seen that three of these studies report a
time interval in the order of 4–6 weeks, all of which report
a positive association between oxaliplatin-based chemo-
therapy and grade 2 sinusoidal dilatation.30,42,43 In contrast,
the two studies that failed to demonstrate such an associ-
ation had longer time intervals, with Ryan et al.32 reporting
a mean of 15 weeks, and in the study of Makowiec et al.,41
26 % of patient had a time interval of over 6 months.
These findings might suggest that the changes of sinusoidal
obstruction syndrome are at least partly reversible with
time, although there is insufficient evidence to prove this.
No association could be demonstrated between the use
of irinotecan-based chemotherapy regimens and the
FIG. 4 Risk of developing grade 2 or greater sinusoidal injury in
patients treated with preoperative chemotherapy (a) and specifically
with oxaliplatin-based regimens (b) or irinotecan-based regimens (c).
The addition of bevacizumab to oxaliplatin-based chemotherapy
reduces the risk of developing grade 2 or greater sinusoidal injury (d)
c
4294 S. M. Robinson et al.
Chemotherapy-Associated Liver Injury 4295
development of grade 2 or greater sinusoidal dilatation (RR
1.11; 95 % CI 0.65–1.90; p = 0.70; Fig. 4c).
In addition to sinusoidal dilatation, more severe sinu-
soidal obstruction syndrome is associated with features
such as nodular regenerative hyperplasia, peliosis, and
parenchymal extinction.44 The presence of these features
was assessed in the series of Rubbia-Brandt et al.,44 who
found that patients treated with oxaliplatin-based chemo-
therapy demonstrated an increased incidence of nodular
regenerative hyperplasia (58 vs. 0 %) compared to che-
motherapy-naive controls. Peliosis was also more common
in patients treated with oxaliplatin-based chemotherapy,
and its presence was linked to the severity of sinusoidal
dilatation being present in 30 % of patients with grade 3
dilatation as compared to 1 % in those with a grades 1 or 2
injury.44 The association between oxaliplatin-based che-
motherapy and nodular regenerative hyperplasia was not
confirmed in the two other studies that reported this out-
come, those of Komori et al.42 and Ryan et al.,32 although
the number of patients treated with oxaliplatin-based che-
motherapy in both these series was small (15 and 24,
respectively).
Bevacizumab is a monoclonal antibody directed against
VEGF-A, a potent mediator of angiogenesis. A number of
publications have recently suggested that the addition of
bevacizumab to conventional oxaliplatin-based regimens
may reduce the incidence of sinusoidal obstruction syn-
drome.44–46 Of the two studies that reported all grades of
sinusoidal dilatation in 115 patients receiving oxaliplatin-
based chemotherapy alongside bevacizumab, there was no
difference in risk when compared to 287 patients receiving
oxaliplatin-based chemotherapy alone (RR 0.86; 95 % CI
0.72–1.04; p = 0.31). Three studies examined the inci-
dence of grade 2 or greater sinusoidal injury, demonstrating
that the addition of bevacizumab to conventional oxalipl-
atin-based regimens reduces the risk of injury by almost
threefold (RR 0.34; 95 % CI 0.15–0.75; p = 0.008;
Fig. 4d). Calculating the number needed to treat reveals
that the addition of bevacizumab to oxaliplatin-based
chemotherapy would be expected to prevent the develop-
ment of sinusoidal obstruction syndrome in one out of
every three patients (95 % CI 2.5–3.7).
DISCUSSION
The role of chemotherapy in the preoperative manage-
ment of patients with colorectal liver metastases is one of
the most keenly debated topics among those treating this
condition.43,47,48 It is universally accepted that patients
with inoperable disease should be treated, where possible,
with aggressive chemotherapy with a view to downstaging
disease such that curative surgery can be offered.11,12,47,49
It has been demonstrated in several series that overall
survival in this patient group compares favorably to those
able to undergo surgery from the outset.13,50,51
What remains much less clear is what role, if any,
preoperative chemotherapy has to play in the management
of patients presenting with operable liver only metastases.
Although the EPOC trial attempted to answer this question,
it is not clear from this study whether the benefits seen in
terms of progression-free survival were attributable to
preoperative therapy, adjuvant therapy, or a combination of
both.14 The major cause for concern when chemotherapy is
used in this context is the potential effects on the hepatic
parenchyma and the subsequent implications this may have
on surgical morbidity and mortality.17,18 In the EPOC
study, it was demonstrated that the incidence of postoper-
ative complications was significantly increased in the
FOLFOX arm as compared to those who underwent sur-
gery alone (25 vs. 16 %; p = 0.04), although there was no
difference in mortality.14
The meta-analysis of published studies we have per-
formed has demonstrated that the nature of the
parenchymal injury that results from preoperative chemo-
therapy cannot be generalized as a global effect but rather
is a regimen-specific phenomenon—that is, irinotecan-
based regimens are associated with steatohepatitis whereas
oxaliplatin-based regimens are associated with sinusoidal
obstruction. It is also noteworthy that the addition of
bevacizumab to oxaliplatin-based regimens appears to
reduce the severity of oxaliplatin-induced sinusoidal
obstruction syndrome, although the number of patients
included in the three studies reporting this is small, and
larger studies are needed to prove the association. Despite
TABLE 2 Chemotherapy details in studies included in studies ana-
lyzing the risk of grade 2 or greater sinusoidal dilatation after
oxaliplatin-based chemotherapy
Study Years Interval between
chemotherapy
and surgery
Number of
chemotherapy
cycles
Aloysius et al.69 2007 – Median 6
Gomez-Ramirez
et al.30
2010 4–6 weeks –
Komori et al.42 2010 Mean 37 days Mean 7.7
Makowiec et al.41 2011 26 % Patients [ 6
months
Median 6
Mehta et al.26 2004 – –
Pawlik et al.31 2007 – 65 % Less than
12 weeks
duration
Ryan et al.32 2010 Mean 15 weeks Mean 8.6
Tamandl et al.40 2011 – Median 6
Vauthey et al.33 2006 Median 6.4 weeks Median 12-week
duration
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the widespread clinical use of the anti-EGFR monoclonal
antibodies cetuximab and panitumumab, there are no
published data regarding their effect on chemotherapy-
induced liver injury. However, they are usually provided in
combination. This is an area that needs clarification.
It is perceived that an increased risk of morbidity in these
patients arises from injury to the hepatic parenchyma, and
this view is supported by a number of studies that have
demonstrated the negative impact of parenchymal disease on
surgical outcome in those having major resection.52–55
Before embarking on a major hepatectomy, it is routine to
make an evaluation of the liver either radiologically (e.g.,
steatosis, splenomegaly) or by using specific tests of hepatic
functional reserve, such as the indocyanine green retention
rate, the MEGX test, or the LiMAx test.56–59 Krieger et al.60
demonstrated that patients who received preoperative che-
motherapy were more likely to have a greater indocyanine
green retention at 15 min as compared to those who are
chemotherapy naive (7.3 vs. 3.5 %; p \ 0.001). A multi-
variate analysis performed by Nakano et al.39 demonstrated
that a preoperative indocyanine green retention rate
of [10 % was an independent predictor of the presence of
sinusoidal injury (RR 4.02; 95 % CI 1.26–12.88; p =
0.019). When it is determined that an individual patient is at
high risk of chemotherapy-induced liver injury, it may be
necessary to modify the planned surgical procedure to spare
more of the liver parenchyma or to use measures such as
portal vein embolization to increase the size of the planned
future hepatic remnant, thereby minimizing the risk of
postoperative liver failure.61 It has been suggested that
hypertrophy of the future liver remnant after portal vein
embolization may be impaired in patients who have received
preoperative chemotherapy, although this is disputed by
others, and further clarification is needed on this subject.62–64
Identifying patients at particular risk of developing a
parenchymal injury after preoperative chemotherapy has
proven difficult. Despite the logical belief that prolonged
chemotherapy exposure is related to an increased incidence
of injury, the evidence in relation to this is difficult to
interpret, with conflicting results being reported, particu-
larly in regard to oxaliplatin-induced sinusoidal obstruction
syndrome, suggesting that the story is perhaps more com-
plicated.39,40 It may be that patients with pre-existing liver
disease are at an increased risk of parenchymal injury,
although the absence of a prechemotherapy liver biopsy
makes it difficult to ascertain to which patient groups
specifically this might apply. It is increasingly recognized
that pharmacogenomics can play a key role in determining
the susceptibility of the individual to the toxic effects of
chemotherapy; for example, patients with mutations in the
UGT1A1 gene have been found to be at increased risk of
systemic toxicity from irinotecan.65 Similarly, oxaliplatin
toxicity is affected by mutations in genes involved in DNA
damage repair and conjugation of its metabolites to glu-
tathione.66 Whether genetic polymorphisms in these or
other genes are able to identify a cohort of patients at
increased risk of chemotherapy-induced parenchymal
injury is not known, but this area may well be worthy of
further exploration.
In conclusion, preoperative chemotherapy is associated
with regimen-specific liver injury. The presence of such an
injury may have a negative impact on the functional
reserve of the liver, thereby increasing the risk of surgical
morbidity and mortality. This should be borne in mind
when planning multimodal treatment for patients with
colorectal liver metastases.
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